<code id='CEEE1DC266'></code><style id='CEEE1DC266'></style>
    • <acronym id='CEEE1DC266'></acronym>
      <center id='CEEE1DC266'><center id='CEEE1DC266'><tfoot id='CEEE1DC266'></tfoot></center><abbr id='CEEE1DC266'><dir id='CEEE1DC266'><tfoot id='CEEE1DC266'></tfoot><noframes id='CEEE1DC266'>

    • <optgroup id='CEEE1DC266'><strike id='CEEE1DC266'><sup id='CEEE1DC266'></sup></strike><code id='CEEE1DC266'></code></optgroup>
        1. <b id='CEEE1DC266'><label id='CEEE1DC266'><select id='CEEE1DC266'><dt id='CEEE1DC266'><span id='CEEE1DC266'></span></dt></select></label></b><u id='CEEE1DC266'></u>
          <i id='CEEE1DC266'><strike id='CEEE1DC266'><tt id='CEEE1DC266'><pre id='CEEE1DC266'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:explore    Page View:24381
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In